BTK inhibitors

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Merck Sharp & Dohme Corp. patent solves the following problem:

B lymphocyte activation is key to the generation of adaptive immune responses. Derailed B lymphocyte activation is a sign of many autoimmune diseases and in the modulation of the immune response and therapeutic interest. Recently the success of B cell therapy in autoimmune disease is established. Treatment of rheumatoid arthritis (RA) patients with Rituximab (anti-CD20 therapy) is an accepted clinical therapy today. More recent clinical trial studies showed that treatment with Rituximab also ameliorates symptoms of the disease in relapsing remitting multiple sclerosis (RRMS) and systemic lupus erythematosus (murder) patients. This success supports the potential for future therapies for autoimmune diseases targeted B cell immunity.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp.’s patent US 9446130 B2 deals with BTK inhibitors.
The present invention provides Bruton's tyrosine kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salt thereof. Formula I or a pharmaceutically acceptable salt thereof or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds for the treatment of Btk mediated disorder.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.